Oncolys BioPharma Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Yasuo Urata
Chief executive officer
n/a
Total compensation
CEO salary percentage | n/a |
CEO tenure | 20.2yrs |
CEO ownership | 2.4% |
Management average tenure | no data |
Board average tenure | 9.2yrs |
Recent management updates
CEO
Yasuo Urata (68 yo)
20.2yrs
Tenure
Mr. Yasuo Urata, M.Sc. has been President and Chief Executive Officer of Oncolys BioPharma Inc. since March 2004. Mr. Urata served various executive functions at Japan Tobacco pharmaceutical division (JT P...
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO, President & Representative Director | 20.2yrs | no data | 2.39% ¥ 352.2m | |
Director of Finance & Accounting | 11.2yrs | no data | 0.086% ¥ 12.7m | |
External Auditor | 12.7yrs | no data | 0.0048% ¥ 705.9k | |
In Charge of CMC Planning and Overseas Leader & Director | 16.2yrs | no data | 0.55% ¥ 81.2m | |
Corporate Auditor | 7.2yrs | no data | 0.0029% ¥ 422.9k | |
Independent External Director | 2.2yrs | no data | no data | |
Outside Auditor | 3.2yrs | no data | no data | |
Independent Outside Director | 1.2yrs | no data | no data |
9.2yrs
Average Tenure
67yo
Average Age
Experienced Board: 4588's board of directors are considered experienced (9.2 years average tenure).